The goal of LambdaVision is to design and develop an innovative, protein-based retinal implant that utilizes the light-activated protein, bacteriorhodopsin, to stimulate the retina of patients suffering from impaired vision or loss of sight due to retinal degenerative diseases, including age-related macular degeneration (AMD) and retinitis pigmentosa (RP). Because current treatments of RP and AMD only slow disease progression, LambdaVision is dedicated to creating a retinal prosthesis that is capable of restoring high-resolution vision and enhancing the quality of life for those afflicted by retinal degeneration. LambdaVision was founded through UConn Ventures in May 2009 by the research group lead by Dr. Robert R. Birge, Distinguished Professor of Chemistry at the University of Connecticut.
